1 STUDY PROTOCOL

2

Protocol for Cerebellar Stimulation for Aphasia Rehabilitation (CeSAR): A randomized, double-blind, sham-controlled trial

5

Authors: Becky Lammers¹, Myra J. Sydnor¹ Sarah Cust¹, *Ji Hyun Kim¹, Gayane Yenokyan⁴,
Argye E. Hillis^{1,2,3}, Rajani Sebastian¹

8

9 ¹Department of Physical Medicine and Rehabilitation, School of Medicine, Johns Hopkins

10 University, Baltimore, MD, ²Department of Neurology, School of Medicine, Johns Hopkins

11 University, Baltimore, MD, ³Department of Cognitive Science, Krieger School of Arts and

12 Sciences, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins Biostatistics Center,

13 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, *currently

14 affiliated with the School of Medicine, New York Medical College, Valhalla, NY

- 15
- 16
- 17 <u>Corresponding Author</u>
- 18 Rajani Sebastian, PhD
- 19 Department of Physical Medicine and Rehabilitation
- 20 Johns Hopkins University School of Medicine
- 21

22 600 N Wolfe Street, Phipps 183

- 23 Johns Hopkins University School of Medicine
- 24 Baltimore, MD 21287, USA
- 25
- 26 Email: rsebast3@jhmi.edu
- 27 Phone: +1 410-502-5012
- **28** Fax: +1 410-502-2419
- 29

30 Abstract

In this randomized, double-blind, sham-controlled trial of Cerebellar Stimulation for Aphasia Rehabilitation (CeSAR), we will determine the effectiveness of cathodal tDCS (transcranial direct current stimulation) to the right cerebellum for the treatment of chronic aphasia (>6 months post stroke). We will test the hypothesis that cerebellar tDCS in combination with an evidenced-based anomia treatment (semantic feature analysis, SFA) will be associated with greater improvement in naming untrained pictures (as measured by the change in Philadelphia Picture Naming Test), 1week post treatment, compared to sham plus SFA. We will also evaluate the effects of cerebellar

38 tDCS on naming trained items as well as the effects on functional communication, content, 39 efficiency, and word-retrieval of picture description, and quality of life. Finally, we will identify 40 imaging and linguistic biomarkers to determine the characteristics of stroke patients that benefit 41 from cerebellar tDCS and SFA treatment. We expect to enroll 60 participants over five years. 42 Participants will receive 15, 25-minute sessions of cerebellar tDCS (3-5 sessions per week) or 43 sham tDCS combined with 1 hour of SFA treatment. Participants will be evaluated prior to the 44 start of treatment, one-week post-treatment, 1-, 3-, and 6-months post treatment on primary and secondary outcome variables. The long-term aim of this study is to provide the basis for a Phase 45 46 III randomized controlled trial of cerebellar tDCS vs sham with concurrent language therapy for 47 treatment of chronic aphasia.

48 Trial registration: The trial is registered with ClinicalTrials.gov <u>NCT05093673</u>.

49

50 Introduction

51 Aphasia is a devastating outcome and one of the leading causes of disability following 52 stroke. Aphasia adds substantial costs to the acute [1] and chronic [2] care of individuals with 53 stroke and is an independent predictor of subsequent functional dependence and death [3]. Anomia 54 or difficulty with naming is the most common deficit in individuals with aphasia. Currently, the 55 most widespread rehabilitation approach for aphasia is speech and language therapy (SALT) [4]. 56 Although the interventions to improve naming can have benefits [5–9], a substantial number of 57 treatment sessions is usually required to show gains, particularly in individuals with chronic large left hemisphere stroke. Therefore, to address how the treatment of aphasia might be made more 58 59 effective, researchers are now using an emerging, safe, non-painful, and low-cost brain stimulation 60 method called transcranial direct current stimulation (tDCS) [10]. There is evidence that tDCS

61 may be useful for enhancing the effects of behavioral aphasia treatment. Evidence is growing that 62 the add-on use of tDCS can aid in the recovery of aphasia as highlighted by international 63 recommendations [11]. However, there is a general lack of consensus regarding the optimal 64 electrode montage for stimulation in post-stroke aphasia. Addressing this barrier is critical for 65 successful clinical translation.

66 Stimulating the residual left hemisphere region is the most common approach based on the 67 observation that optimal recovery involves the functional re-recruitment of the remaining lefthemisphere tissue [12-16]. However, encephalomalacia filled with cerebrospinal fluid at the site 68 69 of stroke affects the electrical current flow, reducing the exposure of the targeted perilesional tissue 70 to stimulation [17]. This issue makes selection of optimal electrode locations in the left hemisphere 71 difficult. Approaches to address this issue involve advanced electrical field modeling methods [18– 20] or individualized electrode placement based on pre-treatment functional magnetic resonance 72 73 imaging (fMRI) scans so that stimulation targets residual functional tissue [21-24]. However, 74 advanced electrical field modeling and fMRI are cost-intensive and require substantial 75 technological expertise. This would limit the incorporation of tDCS into routine speech language 76 pathology clinical practice. We propose a novel approach to augment aphasia treatment by 77 stimulating the right cerebellum. The right cerebellum is not only involved in cognitive and language functions (see [25–27] for reviews) but is also distant enough from typical stroke locations 78 79 associated with aphasia that electrical current flow patterns are unlikely to be affected by the 80 encephalomalacia [17]. In addition, this approach is suitable for patients who have large left 81 hemisphere strokes and aphasia associated with bilateral hemispheric strokes.

In 2017, our group published the first study showing that cerebellar tDCS has the potential
to augment aphasia treatment in a participant with bilateral middle cerebral artery infarct resulting

84 in aphasia [28]. Subsequently, another group, utilizing a crossover study design, showed that 5 85 sessions of cathodal cerebellar tDCS coupled with language treatment improved verb generation 86 immediately post-treatment in chronic post-stroke aphasia [29]. In a follow up study, we conducted 87 a randomized, double-blind, sham controlled, within-subject crossover study in 24 chronic stroke 88 participants with aphasia [30]. We also investigated whether there are any differences in anodal 89 versus cathodal cerebellar tDCS on naming performance as prior studies in healthy controls have 90 shown beneficial language effects for anodal and cathodal cerebellar stimulation [17,31-33]. 91 Participants received 15 sessions of anodal (n=12) or cathodal (n=12) cerebellar tDCS + 92 computerized aphasia therapy in Phase 1 followed by sham + computerized aphasia therapy in 93 Phase 2, or the opposite order. The results of our study revealed several important findings, which 94 have significant implications for the proposed study. First, we found that cerebellar tDCS 95 significantly improved naming in trained (Naming 80) and untrained (Philadelphia Naming Test, 96 PNT [34]) items immediately post-treatment, and the significant improvement in untrained naming was maintained at two months post-treatment. Second, we found that participants receiving 97 98 cathodal stimulation showed significantly greater gains (compared to sham) in naming than 99 participants receiving anodal stimulation, indicating that cathodal stimulation might be more 100 favorable than anodal stimulation to augment aphasia treatment. Thus, these results indicate that 101 cathodal cerebellar tDCS combined with language treatment has the potential to augment aphasia 102 treatment.

tDCS is believed to enhance neural plasticity by temporarily modulating resting membrane potentials of neurons in targeted areas [35,36]. Anodal stimulation may lead to depolarization of the neuronal membranes resulting in greater excitability, whereas cathodal stimulation may lead to hyperpolarization resulting in lower excitability. Because the cerebellar cortex is highly

107 convoluted and the neuronal architecture is different from cortical circuits, the polarity of 108 cerebellar tDCS effects is not necessarily the same as the polarity of cortical tDCS effects. Animal 109 and human studies indicate that cerebellar tDCS is most likely to produce its effects by polarizing 110 Purkinje cells - the inhibitory output neurons of the cerebellar cortex - and thereby changing the 111 levels/pattern of activity in the deep cerebellar output nuclei, which are the efferent targets of the 112 Purkinje cells [37,38]. Critically, one of the deep cerebellar nuclei, the dentate nucleus, has a 113 disynaptic excitatory connection through the thalamus to the cortical language areas. Based on this 114 known circuitry, we hypothesize that a single session of right cathodal cerebellar stimulation will 115 result in transient depression of Purkinje cell activity, thereby reducing the inhibitory signals that 116 the cerebellum sends to the cortical language areas. Anodal cerebellar stimulation will exert the 117 opposite effect, i.e., it will increase the discharge from the Purkinje cells, thereby increasing the 118 inhibitory signals the cerebellum sends to the cortical language areas. Thus, it is plausible that 119 multiple sessions of cathodal cerebellar tDCS will provide cortical excitation, thereby facilitating 120 the engagement of the residual left hemisphere language areas.

121 In this proposal, we will combine cerebellar tDCS with semantic feature analysis (SFA) 122 treatment for post-stroke aphasia (see [39–43] for reviews regarding SFA). SFA is a semantically-123 based treatment approach for naming deficits. SFA was chosen for this study for three main reasons 124 (1) SFA has a strong potential for promoting acquisition and generalization effects for participants 125 with anomia, (2) SFA is an effective therapy for treating naming deficits for individuals with a 126 range of aphasia types and severities, and (3) SFA is a treatment that is frequently used by 127 practicing speech-language pathologists (SLPs). The driving premise of SFA treatment is that 128 when individuals generate semantic features of a target word (i.e., accessing their semantic 129 network), they improve their ability to retrieve the target because they have strengthened access to

its conceptual representation [41,44]. The theoretical mechanism by which SFA promotes generalization comes from the spreading activation theory [45] which posits that accessing/activating a particular lemma (or its features) results in activation of the lemmas of semantically related concepts. Prior studies provide strong compelling evidence that the right cerebellum, the target of our tDCS treatment, is a critical structure involved in semantic processing and naming [25–27,46–48].

136 Here we describe a protocol for an ongoing randomized, double-blind, sham-controlled 137 study of cerebellar tDCS for augmenting anomia therapy in chronic aphasia. Participants are 138 enrolled parallelly at two sites within the Johns Hopkins Rehabilitation Network: Johns Hopkins 139 Hospital and Howard County General Hospital. We hypothesize that 15 sessions of cathodal 140 cerebellar tDCS plus SFA will be associated with greater improvement in naming untrained 141 pictures (as measured by the change in Philadelphia Picture Naming Test, PNT [34], 1-week post 142 treatment, compared to sham plus SFA. For secondary outcomes, we hypothesize that cathodal 143 cerebellar tDCS plus SFA will result in greater improvement in discourse (as measured by change 144 in total content units (CU) and syllable per CU in picture description [49] and greater improvement 145 in functional communication skills (as measured by change in Communication Activities of Daily 146 Living-CADL-3 [50] compared to sham plus SFA. We also hypothesize that 15 sessions of 147 cathodal cerebellar tDCS plus SFA will result in greater improvement on the Western Aphasia 148 Battery-Revised (WAB-R) [51], General Health Questionnaire (GHQ)-12 [52], and Stroke and 149 Quality of Life Scale (SAQOL-39) [53] compared to sham plus SFA.

A second aim is to identify whether neural (functional and structural) biomarkers and linguistic characteristics can predict response to cerebellar stimulation and SFA treatment. Our prior work in cerebellar tDCS in aphasia has shown that individual response to tDCS treatment is

highly variable. However, little is known about how factors related to imaging and linguistic characteristics combine to induce treatment responsiveness. We will carry out resting state functional magnetic resonance imaging (rsfMRI), diffusion tensor imaging (DTI), high resolution structural imaging, and detailed linguistic testing before the start of treatment to determine whether these factors can predict response to cerebellar tDCS and/or SFA. This exploratory aim may identify stroke patients who are mostly likely to benefit from cerebellar tDCS and/or SFA. This result may have significant implications for designing a Phase III randomized controlled trial.

160

161 Materials and Methods

162 Design

163 This study, Cerebellar Stimulation for Aphasia Rehabilitation (CeSAR), is a Phase II trial 164 of cathodal cerebellar tDCS plus SFA treatment vs. sham plus SFA treatment, evaluated in 165 double-blind, randomized, sham-controlled design in chronic stroke. Participants with chronic 166 aphasia are enrolled at two sites within the Johns Hopkins Rehabilitation Network at least 6 167 months after the onset of stroke. The two sites will be the Johns Hopkins Hospital and Howard 168 County General Hospital. Sixty participants are expected to enroll over five years. The SPIRIT 169 schedule of enrollment, interventions, and assessments is included as Fig 1. The World Health 170 Organization Trial Registration Data Set compiled by ClinicalTrials.gov (NCT05093673) is 171 reproduced in Table 1 (SPIRIT Item 2b). The SPIRIT checklist is included in S1 File. A full 172 accounting of evaluations and unabridged protocol approved by the IRB is available in S2 File 173 (September 15, 2023) and important protocol modifications will be available from the 174 corresponding author and by viewing the ClinicalTrials.gov study entry. A sample consent form 175 is included in S3 File.

176 Patient population-inclusion and exclusion criteria

177 Participants must be >6 months post ischemic or hemorrhagic left-hemisphere stroke and 178 diagnosed with post-stroke aphasia and naming impairment using the Western Aphasia Battery-179 Revised (WAB-R). They must also be 18 years or older, premorbidly right-handed, and English-180 speaking by self-report with no lesions on the right cerebellum, with no previous neurological 181 disorder other than stroke, or other neurodegenerative or psychiatric disorders. Individuals with 182 seizures within the previous 6 months, those taking medications that lower the seizure threshold 183 (e.g., methylphenidate) or N-methyl-D-aspartate (NMDA) antagonists (e.g., memantine), and 184 those with a history of brain surgery or with any metal in the head will be excluded. We will also 185 exclude those with uncorrected hearing or vision loss by self-report, those who score >80% on 186 the Philadelphia Naming Test (PNT) at baseline, and those with severely impaired auditory 187 comprehension and/or severely limited verbal output (lower than 2 on the Auditory 188 Comprehension subscore on the WAB-R and/or lower than 2 on the Spontaneous Speech rating 189 scale on the WAB-R, respectively). Individuals with severe claustrophobia, cardiac pacemakers 190 or ferromagnetic implants, and pregnant women will be excluded from the MRI portion of the 191 study.

192 Inclusion Criteria

193 1. Chronic ischemic or hemorrhagic left hemisphere stroke

- 194 2. Fluent speaker of English by self-report
- **195 3**. Age 18 or older
- 196 4. Premorbidly right-handed
- **197 5**. 6 months post onset of stroke

198	6.	Diagnosis of aphasia and naming impairment using the Western Aphasia Battery-
199		Revised
200	Exclusion	Criteria
201	1.	Lesion in the right cerebellum
202	2.	Previous neurological disorder (other than stroke) affecting the brain, or any other
203		neurodegenerative disorder or psychiatric disorder
204	3.	Seizures during the previous 6 months
205	4.	Uncorrected visual loss or hearing loss by self-report
206	5.	Use of medications that lower the seizure threshold (e.g., methylphenidate)
207	6.	Use of N-methyl-D-aspartate (NMDA) antagonists (e.g., memantine)
208	7.	>80% correct response on the Philadelphia Naming Testing at baseline
209	8.	History of brain surgery or any metal in the head
210	9.	Severely impaired auditory comprehension (lower than 2 on the Comprehension
211		subscore on the Western Aphasia Battery-Revised)
212	10.	Severely limited verbal output (lower than 2 on the Spontaneous Speech rating scale
213		on the Western Aphasia Battery-Revised)
214	11.	Individuals with severe claustrophobia, cardiac pacemakers or ferromagnetic
215		implants, and pregnant women will be excluded from the MRI portion of the study.
216		
217		
218		
219		
220		

Data category Information Primary registry and trial ClinicalTrials.gov NCT05093673 identifying number Date of registration in October 13, 2021 primary registry IRB00300301 Secondary identifying numbers Source(s) of monetary or National Institute on Deafness and Other Communication Disorders (NIH/NIDCD) material support R56DC019639 R01DC019639 Note: This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. Primary sponsor Johns Hopkins University Secondary sponsor(s) None Contact for public Rajani Sebastian, PhD, CCC-SLP (410) 502-5012 rsebast3@jhmi.edu queries Contact for scientific Rajani Sebastian, PhD, CCC-SLP (410) 502-5012 rsebast3@jhmi.edu queries Public title Cerebellar Stimulation for Aphasia Rehabilitation (CeSAR) Scientific title Cerebellar Stimulation for Aphasia Rehabilitation (CeSAR) Countries of recruitment United States of America Health condition(s) or Aphasia, Stroke problem(s) studied Intervention(s) tDCS: 2 mA of cathodal tDCS stimulation via Soterix Medical 1x1 Clinical Trials device Placebo: sham tDCS via Soterix Medical 1x1 Clinical Trials device • • Current will be ramped up over a 15 second interval at onset, then current intensity will be ramped down over a 15 second interval to 0 mA to mimic active tDCS Behavioral: Computer-delivered anomia treatment (SFA) Semantic Feature Analysis (SFA) • 15 hour-long sessions of SFA (3-5 sessions per week for 3 to 5 weeks) • Key inclusion and **Inclusion** Criteria exclusion criteria Chronic ischemic or hemorrhagic left hemisphere stroke . Fluent speaker of English by self-report • Age 18 or older Premorbidly right-handed • 6 months post onset of stroke • . Diagnosis of aphasia and naming impairment using the Western Aphasia Battery-Revised **Exclusion Criteria** Lesion in the right cerebellum Previous neurological disorder (other than stroke) affecting the brain, or any other neurodegenerative disorder or psychiatric disorder Seizures during the previous 6 months Uncorrected visual loss or hearing loss by self-report Use of medications that lower the seizure threshold (e.g., methylphenidate) Use of N-methyl-D-aspartate (NMDA) antagonists (e.g., memantine) >80% correct response on the Philadelphia Naming Testing at baseline History of brain surgery or any metal in the head Severely impaired auditory comprehension (lower than 2 on the Comprehension subscore on the Western Aphasia Battery-Revised) Severely limited verbal output (lower than 2 on the Spontaneous Speech rating scale on the Western . Aphasia Battery-Revised) Individuals with severe claustrophobia, cardiac pacemakers or ferromagnetic implants, and pregnant women . will be excluded from the MRI portion of the study. Study type Interventional • Allocation: Randomized • Intervention Model: Parallel

221 Table 1. World Health Organization Trial Registration Data Set.

	 Masking: Quadruple (Participant, Assessment Provider, Treatment Provider, Biostatistician) Primary Purpose: Treatment Phase II
Date of first enrollment	12/15/2021
Sample size	Target enrollment total: 60 Current enrollment: 15
Recruitment status	Recruiting: participants are being recruited and enrolled
Primary outcome(s)	Untrained picture naming: Change in Philadelphia Naming Test accuracy. Scores range from 0 to 175 with higher scores meaning better naming ability. [Time Frame: Baseline, 1-week after treatment]
Key secondary outcomes	 Intraine: Date internation: Change in Philadelphia Naming Test accuracy score. Scores range from 0 to 175 with higher scores meaning better naming ability. [Time Frame: Baseline, 1-month after treatment, 3-months after treatment, 6-months after treatment] 2. Trained picture naming: Change in naming items trained during treatment. Scores range from 0 to 50 with higher scores indicating better naming ability. Types of naming errors will also be analyzed. Naming errors will be categorized as 1) semantic paraphasias; 2) phonological paraphasias; 3) mixed (phonological and semantic) paraphasias; 4) non-responses; and 5) unrelated responses. [Time Frame: Baseline, 1-week after treatment, 1-month after treatment, 3-months after treatment, 6-months after treatment] 3. Discourse: Change in discourse abilities, as measured by change in total Content Units (CU) produced by participants during "Cookie Theft" picture description. Content units are based on a standard scoring template of commonly identified concepts in the left and right regions of the "Cookie Theft" picture. Participants either include or fail to include 53 total concepts on the picture (30 concepts on the left side and 23 concepts on the right side). [Time Frame: Baseline, 1-week after treatment, 1-month after treatment, 3-months after treatment, 6-months after treatment] 4. Discourse: Change in discourse abilities, as measured by change in syllables per Content Units (CU) produced by participants during "Cookie Theft" picture description. Syllables produced during the picture description task are counted. Units included during picture description are counted (53 total; 30 left side; 23 right side). The rate of syllables per Content Unit (syllables/CU) is calculated and interpreted as a measure of efficiency in producing information relevant to the task. [Time Frame: Baseline, 1-week after treatment, 1-month after treatment, 3-months after treatment, 6-m
Ethics review	Status: Date of approval: Nome of approval:
Completion date	Name and contact details of Etnics committee(s):
Summary results	
IPD sharing statement	

223 Informed consent

A signed and dated informed consent form will be obtained from each participant. For participants who cannot consent for themselves, a legally authorized representative, such as a legal guardian or power of attorney, must sign the consent form. The consent form will describe the purposes, procedures, risks, and benefits of participation in the study, as well as the participant's ability to withdraw consent at any time without retaliation or impact on clinical care. A copy will be given to each participant or legally authorized representative.

Once the consent form has been signed, participants will be assigned a temporary identificationnumber for the purposes of initial screening.

All research staff authorized to obtain informed consent will have completed the Miami CITI course in the Responsible Conduct of Research and Protection of Human Subjects prior to their involvement with the study. Furthermore, they will be oriented to the study and trained by the study PI and study co-investigators who have all had extensive training and experience in the ethical and practical aspects of informed consent procedures.

237 Participant confidentiality

238 Participation in this study should not put participants in any legal risk, even in the case of 239 a breach of confidentiality. We will undertake every effort to keep the information in the study 240 confidential. Participants will be assigned a code number in order to keep protected health 241 information confidential. Consent forms and source documents will be maintained at the PI lab in 242 a locked cabinet. All digital data will be done using participant identification numbers only and 243 will be stored on a password-protected and encrypted format in a manner that is Johns Hopkins 244 IRB compliant. This will include the Clinical Research Management System (CRMS), Research 245 Electronic Data Capture (REDCap), and Johns Hopkins Microsoft One Drive. All are web-based

applications designed to organize and streamline clinical research management. CRMS is integrated with Epic, Hopkins enterprise EMR, as well as Johns Hopkins IRB. This integration improves communication among study team members, stores subject enrollment information in a secure location, assists with recruitment, and allows research results to be promptly incorporated into the EMR. Everybody involved in the study will have completed the appropriate HIPAA training and are fully aware of confidentiality issues. No names will be included in any publications resulting from this work.

253 Randomization

254 Prior to randomization, all eligible participants will receive comprehensive language and 255 cognitive evaluations as well as MRI for those who consent and who have no contraindication. 256 Participants will be randomly assigned 1:1 (cerebellar cathodal tDCS plus SFA treatment or sham 257 tDCS plus SFA treatment). The randomization is stratified by study site (JHH vs Howard County), 258 aphasia type (fluent vs. non-fluent, classified using WAB-R), and aphasia severity. Aphasia 259 severity will be classified using WAB-R Aphasia Quotient in 4 categories (very severe aphasia: 260 0-25, severe aphasia: 26-50, moderate aphasia: 51-75, and mild aphasia: 76-93.8). Covariate-261 adaptive randomization method developed by Pocock and Simon, 1975 [54] will be implemented 262 in REDCap. This method ensures balance on important baseline covariates by treatment arm by 263 calculating the difference in these covariates (site, aphasia type and severity) each time a 264 participant needs be randomized and then randomizes with high probability (80%) to the arm that 265 corrects the imbalance on covariates.

The SLP will enter the baseline and eligibility information of a participant prior to enrollment on REDCap. If the participant's eligibility is confirmed, then the algorithm implemented in REDCap will evaluate the treatment arm distribution in participants already

randomized and then generate treatment allocation group (sham or tDCS) based on the randomization scheme. Each participant will receive a unique six-digit codes (provided by the manufacturer of the tDCS stimulator), which will instruct the stimulator to deliver either active stimulation or placebo (sham). These codes will be entered into REDCap prior to starting the study. The study coordinator will enter the codes in REDCap.

Both groups will receive semantic feature analysis treatment, a commonly used treatment for naming deficits in aphasia. It is currently unknown whether or not cerebellar tDCS augments the effect of semantic feature analysis in the chronic phase after stroke. Therefore, a sham group is justified.

278 Blinding

The study is to be conducted in a double-blind manner. All participants, the members of the study team who administer the assessments, those who administer treatments, as well as the study biostatistician performing the statistical analyses will be blinded.

282 Imaging

The MRI scans will be performed prior to the start of the study on a 3T Philips system at the F.M. Kirby Center at the Kennedy Krieger Institute. Imaging will be done for patients who have no MRI contraindications. Imaging will include structural and functional scans. Structural scans will include high resolution T1 and T2 weighted images, Fluid Attenuation Inversion Recovery (FLAIR) scans, and Diffusion Weighted Imaging (DWI) images. Functional scan will include resting state functional MRI.

289 Treatment

290 Participants will receive 15 sessions of SFA treatment (3-5 sessions per week over the 291 course of 3 to 5 weeks) and each session will be 60 minutes. Prior to the start of treatment, 292 participants will be randomly assigned to receive either sham plus SFA or active tDCS plus SFA. 293 The SLP will start the Semantic Feature Analysis Treatment. Participants will receive SFA 294 treatment for 60 minutes and tDCS for the first 25 minutes. SFA treatment employed in this study 295 will include 50 items and their relevant features from eight semantic categories. Items included in 296 each participant's treatment list will be determined based on performance on a picture-naming task. 297 The naming task will consist of 200 items across eight semantic categories (food [fruits, 298 vegetables], animals, transportation, clothing, furniture, music, sports, toys). The naming task will 299 be administered once. To qualify for treatment, an item must be named incorrectly. To avoid 300 effects of repeated exposure, items included on the naming task will be constrained such that they 301 do not occur in the primary outcome variable (PNT).

302 Therapy tasks will be administered through a computer with clinician assistance using 303 Microsoft Powerpoint. Participants will be trained on 7-12 items per session depending on each 304 participant's aphasia severity. The treatment protocol will be adapted from Doyle, Dickey and 305 colleagues [55,56]. The treatment will proceed according to a series of steps including naming 306 aloud the target picture, generating semantic features, naming aloud the target picture again, and 307 generating a sentence using the target word. Participants will be asked to generate semantic 308 features for each target picture in five categories: group [superordinate category], function 309 [use/action], description [physical properties], context [location], and other/personal [association]. 310 A three-level cueing hierarchy will be used to elicit features, consisting of general prompt (e.g., 311 "How would you describe this?"), followed by a relevant directed question (e.g., "What does this 312 feel like?") and a binary forced-choice question (e.g., "Is this item smooth or rough?").

313 tDCS will be delivered for 25 minutes using the Soterix Medical 1x1 Clinical trials device. 314 Soterix 1×1 CT is the most advanced and customizable system for true double-blind control trials. 315 Consistent with other studies on cerebellar tDCS [28-30,57], the current study will utilize 2 mA 316 of cathodal tDCS stimulation generated between two 5 cm x 5 cm saline-soaked sponges. The 317 active electrode (cathode) will be placed on the right cerebellar cortex, 1 cm under and 4 cm lateral 318 to the inion (approximately comparable to the projection of cerebellar lobule VII onto the scalp 319 [31]. The reference electrode (anode) will be placed over the right shoulder. For both tDCS and 320 sham interventions, current will be ramped up over a 15 second interval at stimulation onset, 321 eliciting a transient tingling sensation that effectively blinds the participant to treatment condition 322 [58]. After the ramp up, in the sham condition, current intensity will be ramped down over a 15 323 second interval to 0 mA. Participants will rate their pain levels at the end of stimulation with the 324 Wong-Baker FACES Pain Rating Scale (wongbakerfaces.org) [59]. In each session, participants 325 will be asked to inform the SLP about any side effects. Participants generally tolerate tDCS well, 326 the main reported side effects being initial tingling or itching sensations at the beginning of the 327 session for some participants [60]. Stimulation (for both tDCS and sham conditions) will start at 328 the same time as the aphasia treatment. Aphasia treatment will continue for another 35 minutes 329 after the completion of 25 minutes of real tDCS or sham tDCS for a total of 60 minutes per session.

Intervention for a participant will be discontinued if any of the following criteria are met:
Participants will be removed from the study if they are unable to comply with task instructions or
tolerate the tDCS procedure.

When the study ends, participants will continue to receive management with Dr. Argye Hillis (study neurologist) or their own neurologist as usual (generally follow-up visits approximately every 12 months). If a patient's participation in the study ends prematurely s/he will still receive care as before. In sum, termination of the study or termination of participation in itwill not affect regular therapy he or she may be receiving.

338 **Primary outcome**

The primary outcome will be defined as the change in accuracy of naming untrained pictures measured by the Philadelphia Naming Test (PNT), one week after the end of semantic feature analysis (SFA).

342 Secondary outcomes

343 In addition to the primary outcome, several secondary analyses will be conducted. (1) 344 Trained Picture Naming. We will assess if tDCS has an effect on naming items trained during 345 treatment (trained picture naming). We will assess change in trained picture naming before 346 treatment to within 1 week after the end of treatment. Follow up testing will be done at one month, 347 three months and six months after the completion of the treatment. In addition to assessing changes 348 in correct naming, we will also evaluate treatment-related changes in naming errors to provide 349 additional insight into naming recovery following cerebellar tDCS. Naming errors will be 350 categorized as 1) semantic paraphasias; 2) phonological paraphasias; 3) mixed (phonological and 351 semantic) paraphasias; 4) non-responses; and 5) unrelated responses. (2) Discourse. We will assess 352 change in discourse abilities, as measured by the change in the total Content Units (CU) and 353 syllable per CU produced by the participants during connected speech. Participants will be 354 required to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. 355 (3) Functional Communication Skills. We will also measure changes in everyday functional 356 communication skills assessed with the Communication Activities of Daily Living, third edition (CADL-3). (4) Finally, we will administer 3 tests from the Research Outcome Measurement in 357 358 Aphasia-Core Outcome Set (ROMA-COS) at baseline, 1-week post treatment, and follow up time

points. The WAB-R will be administered as a part of the baseline testing. We will also assess
changes in emotional wellbeing (measured by General Health Questionnaire (GHQ)-12 and quality
of life (measured by Stroke and Aphasia Quality of Life Scale (SAOOL-39).

362 Data collection and quality assurance

All research staff authorized to obtain informed consent will have completed the Johns Hopkins University School of Medicine's required training in the Responsible Conduct of Research and Protection of Human Subjects prior to their involvement with the study. Furthermore, they will be oriented to the study and trained by the study PI and study coinvestigators who have all had extensive training and experience in the ethical and practical aspects of informed consent procedures.

The PI as well as the SLPs who administer baseline testing, treatments, and follow-up testing will be blinded to participant treatment assignments (described in full in the protocol provided in the Supplemental Materials). Participants will be assigned a code number in order to keep protected health information confidential. Consent forms and source documents will be maintained at the PI lab in a locked cabinet. All digital data will be done using participant identification numbers only and will be stored on a password-protected and encrypted format in a manner that is Johns Hopkins IRB compliant.

The PI (an ASHA certified SLP) will provide training to the two ASHA certified SLPs for scoring and administration of the assessment materials as well as the SFA treatment protocol. To ensure quality control, all assessment sessions and part of the treatment sessions will be videotaped. The PI will create a written protocol for clinicians regarding assessment and scoring, and to ensure consistency of delivery and adherence to SFA treatment protocol. This will reduce clinician-to-clinician variability, clinician drift, and contamination.

With respect to language assessment, the PI will be present for the first few assessment sessions to assure fidelity during assessment. This will be followed by regular monitoring to ensure adherence to assessment administration procedures. All deviations will be reviewed and clarified with the clinician to ensure that adherence is improved in subsequent sessions. Each clinician will have 20% of their total assessment sessions monitored quarterly for accurate implementation.

387 With respect to SFA treatment, the PI will be present for the initial few sessions to assure 388 fidelity during treatment implementation. Following this, treatment fidelity will be monitored on 389 a weekly basis by a member of the study team who is not providing treatment by reviewing short 390 video-recorded segments of treatment for adherence to the SFA protocol using a Treatment 391 Fidelity Checklist. All deviations will be reviewed and clarified with the treating clinician to ensure 392 that adherence is improved in subsequent sessions. When session monitoring detects < 1 deviation 393 across three consecutive samples, sessions will be monitored once bi-weekly for the remainder of 394 the 3–5-week (3-5 sessions per week) treatment period. If session monitoring detects >1 deviations 395 across three consecutive samples, sessions will be monitored daily until deviation is less than one. 396 The PI and research team members meet weekly (or more often) to discuss questions about and 397 implementation of the protocol.

To minimize the need for research-only in-person visits, telemedicine visits will be substituted for portions of clinical trial visits where determined to be appropriate and where determined by the investigator not to increase the participants risks. For the current study, we will utilize telemedicine visits when appropriate for consenting and for all the assessments visits (visits 1- 3, 20-23). Prior to initiating telemedicine for study visits the study team will explain to the participant what a telemedicine visit entails and confirm that the study participant is in agreement and able to proceed with this method. Telemedicine acknowledgement will be obtained in

405 accordance with the Guidance for Use of Telemedicine in Research. In the event telemedicine is 406 not deemed feasible, the study visit will proceed as an in-person visit. Telemedicine visits will be 407 conducted using HIPAA compliant method approved by the Johns Hopkins Health System and 408 within licensing restrictions.

409 Sample size estimates

410 Sample size was determined based on the PI's prior crossover trial data [30]. That data 411 was used to estimate the variability of untrained naming score. Enrolling 52 participants (26 per 412 group) will give us 80% statistical power to detect 0.7 SD difference in change in accuracy of 413 naming untrained items at 1-week post treatment between the study arms. This was done using 414 Wald test for group assignment coefficient in linear regression at 0.1 level of statistical 415 significance. The effect size (0.7SD) is a bit conservative compared to the difference observed on 416 group comparison for 21 participants (10 in tDCS and 11 in sham) in the crossover trial data, when 417 the tDCS was administered in Phase 1. We propose to enroll 60 participants to account for 10% 418 attrition. However, if we have trouble meeting recruitment/retention goals, we will add Johns 419 Hopkins Bayview Medical Center as a site.

420 Statistical analyses

The primary outcome variable will be change in accuracy of naming untrained items as measured by the PNT within 1 week after semantic feature analysis ends. The analyses will follow the Intention-to-treat (ITT) principle where participants are analyzed based on the group to which they are randomized regardless of early termination, missing data or errors in randomization detected post hoc. The primary hypothesis is H_0 : $mu_1 = mu_2$ versus H_A : $mu_1 \neq mu_2$, where mu_1 is the mean change in accuracy of naming untrained items between baseline and 1-week postsemantic feature analysis in the tDCS group and mu_2 is the mean change in accuracy of naming

untrained items between baseline and 1 week post semantic feature analysis in the sham group.
Average Treatment Effect (ATE) will be estimated using linear regression model with change in
accuracy of naming untrained items at 1 week as the dependent variable and group assignment
(real tDCS versus sham) as the independent variable. ATE is estimated by the coefficient for the
group assignment.

As a secondary analysis, we will consider non-parametric mixed models for analyses of 433 functional response over time. In particular, let $Y_{ijk} = u_{ik} + fk(j) + e_{ij}$ where Y_{ij} is the the outcome 434 435 for subject i on occasion j (0, 1, 3, 6) within treatment arm k. (Thus, both i and k are necessary to identify a subject). No covariates are necessary because of the randomization. $f_k(j)$ is a functional 436 437 model we will estimate using quadratic regression splines with knot points at each of the time 438 points. Given there are so few time points, we will not penalize the spline fit. A non-parametric estimate of a treatment effect is given by $f_2 - f_1$, which can show time-specific treatment effects 439 440 when evaluated at specific points j. This will also demonstrate the rate (when and if) at which TCDS effects ebb. An overall effect can be estimated by simply taking the integral of $f_2 - f_1$ (i.e. 441 the functional averaged effect over time). A null hypothesis of zero represents no time averaged 442 443 effect of the treatment. Given that we will use regression splines, every estimator reduces to 444 standard contrasts of regression parameters, and thus can be implemented in any statistical 445 software package. Statistical analysis of secondary outcome variables will follow a similar 446 approach as the primary outcome variable.

An additional goal of this project is to identify whether neural (functional and structural)
biomarkers and linguistic characteristics can predict response to cerebellar stimulation and SFA
treatment. This analysis considers moderation of treatment effects by pre-treatment baseline

450	characteristics. The pre-treatment baseline characteristics include the following: Imaging:						
451	Structural (lesion volume, site, FA, MD), Functional (Fisher transformed connectivity values						
452	(z scores); Linguistic: (Aphasia Severity score as assessed by WAB-R, Naming severity score						
453	assessed by PNT). As in Hypothesis 1, we will consider both a conservative approach, using						
454	standard contrasts and median splits on the moderating variables as well as a mixed model						
455	functional approach. We will proceed in this order:						
456	1. T-test comparing the treatment effect across median splits of the moderating variables						
457	performed separately, one at a time.						
458	2. A non-parametric modeling approach using spline based linear models testing						
459	whether the potential moderating variables interact with the treatment effect over						
460	time. We will consider two variations of this approach:						
461	a. One that assumes linearity						
462	b. One that assumes non-parametric functions						

463 Data Monitoring body

464 The DSMB consists of scientists in Neurology and Public Health and will monitor safety at least semi-annually and decide if the study should continue or be terminated early. DSMB 465 members include Kyrana Tsapkini, PhD (School of Medicine, Johns Hopkins University), John 466 467 W. Krakauer, MD (School of Medicine, Johns Hopkins University), and Constantine Frangakis, 468 PhD (Bloomberg School of Public Health, Johns Hopkins University). The study SLP in 469 consultation with the study biostatistician will generate reports semi-annually or more frequently, 470 as determined by the DSMB, which provide statistics on enrollment, participant status, safety data, 471 and data quality information.

472 Specification of safety parameters

473 The participant may stop testing or the intervention at any time. tDCS provides a non-474 invasive method to stimulate the cortex and cerebellum and modulate cortical/cerebellar activity 475 via continuous, weak polarizing electrical current. This study will use the Soterix Medical 1X1 476 Clinical Trials system to administer tDCS. The Soterix transcranial Direct Current Stimulator 477 Clinical Trials (1x1-CT) system is the most advanced and customizable stimulation for true 478 double-blind control trials. It is powered by four 9-V batteries with an output of 1-2.5 milliamperes 479 (mA). Anodal tDCS (A-tDCS) results in an increase in cortical excitability. Cathodal tDCS results 480 in decrease in cortical excitability. To date, no serious adverse effects of tDCS have been reported 481 in the literature as long as safety guidelines are followed [11,61]. A recent review updated and 482 consolidated the evidence on the safety of tDCS [60]. This review shows that the use of 483 conventional tDCS protocols in human trials (<40 min, <4 mA) has not produced any reports of a 484 serious adverse effect or irreversible injury across over 33,200 sessions and 1000 subjects with 485 repeated sessions. This includes a wide variety of subjects, including participants with stroke. 486 Very minor side effects such as itching, tingling, burning have been reported, as well as temporary 487 headache, sleepiness, dizziness. However, they were generally indistinguishable from those 488 reported by participants receiving sham stimulation. The current study will only administer 2 mA 489 for 25 minutes per treatment session. It is important to note that tDCS does not cause significant 490 heating effects under the electrodes, alter the blood-brain barrier, or induce edema.

491 Our recent study in chronic post stroke aphasia (20 min, 2mA) in 24 participants did not 492 produce any negative effects associated with tDCS administration beyond mild itching/tingling at 493 the beginning of the treatment session [30]. A recent large crossover trial in 36 participants with 494 Primary Progressive Aphasia (20 min, 2mA) reported no episodes of intolerability and no serious 495 adverse effects [62]. On the Wong-Baker FACES Pain Rating Scale, the mean pain rating for tDCS

496 was 2.21 (standard deviation 2.48, range 0–10) and the mean rating for sham was 2.14 (standard
497 deviation 2.13, range 0–10).

498 Another large, randomized control trial in 74 participants with aphasia reported 8 mild, 499 non-serious adverse events and there were no statistically significant differences between 500 treatment groups for number of adverse events [21]. 2 participants (6%) in the active tDCS group 501 experienced transient scalp redness/irritation (erythema) compared with none in the sham tDCS 502 group. On the Wong-Baker FACES Pain Rating Scale, most often individuals reported no hurt: 503 94% (n = 476) in the active tDCS group vs 86% (n = 511) in the sham group. The highest pain 504 rating reported was 3 (indicating "hurts even more"), which was reported 4 times by 2 individuals 505 (3%), both in the sham group. Taken together, all available research suggests that prolonged 506 application should not pose a risk of brain damage when applied according to safety guidelines.

507 Participants may undergo MRI scanning in the present study. The effects of undergoing 508 MR scanning have been extensively studied and there are no risks associated with an MR exam. 509 The patient may, however, be bothered by feelings of confinement (claustrophobia), and by the 510 noise made by the magnet during the procedure. They will be asked to wear earplugs or earphones 511 while in the magnet.

All MRI scans will be reviewed by co-investigator and board-certified neurologist (Dr. Argye Hillis) and any suspicious abnormalities will be referred to a board-certified neuroradiologist. Please note that all of our participants, who will be recruited from the outpatient or stroke clinic, who do not have contraindication for MRI will have had a clinical MRI poststroke. If unexpected abnormalities - incidental findings - are seen (which is unlikely, as every patient will have had a clinical MRI as part of their evaluation for stroke), the participant will be

asked permission to contact the primary care physician about the abnormality, and will be offered
a timely appointment with a neurologist (Dt. Argye Hillis, co-investigator) if appropriate.

520 Participants will be carefully screened over the phone prior to being scheduled, to assure 521 that they meet study criteria. tDCS stimulation will be ramped up over the first 15 seconds of 522 stimulation in order to eliminate the sensation of tingling that can occur under the electrodes during 523 the initial moments of tDCS application. The participant may stop testing or the intervention any 524 time. There will be emergency personnel and equipment on hand for safety.

525 Adverse events will be monitored during the entire visit by the study team. The families 526 will be given telephone numbers of the study team as well. The study physician (Dr. Argye Hillis) 527 and the DSMB will be notified immediately if any adverse events are reported. If a significant 528 safety concern arises, participants may be unblinded in order to address it. The DSMB will 529 determine if the adverse event is a serious adverse event. Adverse events will be monitored until 530 they are resolved or clearly determined to be due to a subject's stable or chronic condition or 531 intercurrent illness. In the case of any unexpected adverse events involving risks to participants or 532 others that are related/possibly related to the research, a Protocol Event Report will be prepared by 533 the Study Coordinator, the PI will be informed immediately, and the IRB will be contacted within 534 10 days as per Johns Hopkins Medicine IRB policy; deaths will be reported within 72 hours. Also, 535 as required by IRB policy, any unexpected adverse device effects, potential breaches of 536 confidentiality, unresolved participant complaints will be promptly reported to the IRB. Any other 537 adverse events that do not require prompt reporting will be summarized and reported to the IRB at 538 the time of continuing review.

539 Summary and concluding remarks

540 It is our hope that completion of this project will result in better understanding of whether 541 and how cerebellar tDCS coupled with behavioral therapy may help individuals with post stroke 542 aphasia. The cerebellum, which contains more than half of the brain's neurons and a significant 543 source of input to language as well as motor cortical regions, provides a means by which residual 544 cortical tissue can be stimulated in stroke participants without interference from the lesion itself. 545 However, the effect of cerebellar tDCS combined with behavioral therapy remains incompletely 546 understood. Further, little is known about how factors related to imaging and linguistic 547 characteristics combine to induce treatment responsiveness. We will carry out resting state 548 functional magnetic resonance imaging (rsfMRI), diffusion tensor imaging (DTI), high resolution 549 structural imaging, and detailed linguistic testing before the start of treatment to determine whether 550 these factors can predict response to cerebellar tDCS and/or SFA. This exploratory aim may 551 identify stroke patients who are mostly likely to benefit from cerebellar tDCS and/or SFA. This 552 result may have significant implications for designing a Phase III randomized controlled trial. Trial 553 results will be submitted to Clinicaltrials.gov no later than one year after the primary completion 554 date. In addition, regardless of outcome, results will be disseminated in peer reviewed journals and 555 contribute to the growing body of literature on the topic of tDCS in post-stroke aphasia 556 rehabilitation.

557 **Funding:** The trial is fully funded by the National Institute on Deafness and Other

Communication Disorders (NIH/NIDCD) R01 DC019639. The funders had and will not have a
role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.

561 **Competing interests:** The authors have declared that no competing interests exist.

562 Supporting Information

- 563 S1 File. SPIRIT checklist.
- 564 (DOCX)
- 565 S2 File. Protocol.
- 566 (DOCX)
- 567 S3 File. Consent Form.
- 568 (PDF)

569 Author Contributions

- 570 **Conceptualization:** RS, AEH
- 571 Data curation: NA
- 572 Formal analysis: NA
- 573 Funding acquisition: RS
- 574 Methodology: RS AEH GY
- 575 **Project administration:** BL, MJS, SC, JHK
- 576 Supervision: RS
- 577 Writing original draft: BL, MJS
- 578 Writing review & editing: BL, MJS, SC, JHK, GY, AEH, RS
- 579
- 580
- 581

582 **References**

- Boehme AK, Martin-Schild S, Marshall RS, Lazar RM. Effect of aphasia on acute stroke outcomes. Neurology. 2016;87: 2348–2354. doi:10.1212/WNL.0000000000003297
 Ellis C, Simpson AN, Bonilha H, Mauldin PD, Simpson KN. The One-Year Attributable Cost of Poststroke Aphasia. Stroke. 2012;43: 1429–1431.
- 587 doi:10.1161/STROKEAHA.111.647339
- 588 3. Tsouli S, Kyritsis AP, Tsagalis G, Virvidaki E, Vemmos KN. Significance of Aphasia after

- First-Ever Acute Stroke: Impact on Early and Late Outcomes. Neuroepidemiology.
 2009;33: 96–102. doi:10.1159/000222091
 Raymer AM, Conzalez-Rothi L, editors. The Oxford handbook of aphasia and lang.
- Raymer AM, Gonzalez-Rothi LJ, editors. The Oxford handbook of aphasia and language
 disorders. New York, NY: Oxford University Press; 2018.
- 593 5. Hillis AE. Treatment of naming disorders: New issues regarding old therapies. J Int 594 Neuropsychol Soc. 1998;4: 648–660. doi:10.1017/S135561779846613X
- 595 6. Nickels L. Therapy for naming disorders: Revisiting, revising, and reviewing. Aphasiology. 2002;16: 935–979. doi:10.1080/02687030244000563
- Raymer AM, Kohen F, Blonder LX, Douglas E, Sembrat JL, Rothi LJG. Effects of gesture and semantic-phonologic treatments for noun retrieval in aphasia. Brain Lang. 2007;103: 219–220. doi:10.1016/j.bandl.2007.07.014
- 8. Wisenburn B, Mahoney K. A meta-analysis of word-finding treatments for aphasia.
 Aphasiology. 2009;23: 1338–1352. doi:10.1080/02687030902732745
- 602 9. Kiran S, Thompson CK. The Role of Semantic Complexity in Treatment of Naming Deficits:
 603 Training Semantic Categories in Fluent Aphasia by Controlling Exemplar Typicality. J
 604 Speech Lang Hear Res JSLHR. 2003;46: 773–787.
- 605 10. Crinion JT. Transcranial Direct Current Stimulation as a Novel Method for Enhancing
 606 Aphasia Treatment Effects. Eur Psychol. 2016;21: 65–77. doi:10.1027/1016-9040/a000254
- Lefaucheur J-P, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, et al.
 Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017;128: 56–92. doi:10.1016/j.clinph.2016.10.087
- 610 12. Fridriksson J, Richardson JD, Fillmore P, Cai B. Left hemisphere plasticity and aphasia 611 recovery. NeuroImage. 2012;60: 854–863. doi:10.1016/j.neuroimage.2011.12.057
- Hamilton RH, Chrysikou EG, Coslett B. Mechanisms of aphasia recovery after stroke and
 the role of noninvasive brain stimulation. Brain Lang. 2011;118: 40–50.
 doi:10.1016/j.bandl.2011.02.005
- Fridriksson J. Preservation and Modulation of Specific Left Hemisphere Regions is Vital for
 Treated Recovery from Anomia in Stroke. J Neurosci. 2010;30: 11558–11564.
 doi:10.1523/JNEUROSCI.2227-10.2010
- Hartwigsen G, Saur D. Neuroimaging of stroke recovery from aphasia Insights into
 plasticity of the human language network. NeuroImage. 2019;190: 14–31.
 doi:10.1016/j.neuroimage.2017.11.056
- 621 16. Saur D, Lange R, Baumgaertner A, Schraknepper V, Willmes K, Rijntjes M, et al.
 622 Dynamics of language reorganization after stroke. Brain. 2006;129: 1371–1384.
 623 doi:10.1093/brain/awl090
- Turkeltaub PE, Swears MK, D'Mello AM, Stoodley CJ. Cerebellar tDCS as a novel
 treatment for aphasia? Evidence from behavioral and resting-state functional connectivity
 data in healthy adults. Hamilton R, editor. Restor Neurol Neurosci. 2016;34: 491–505.
 doi:10.3233/RNN-150633
- 18. Datta A, Baker JM, Bikson M, Fridriksson J. Individualized model predicts brain current
 flow during transcranial direct-current stimulation treatment in responsive stroke patient.
 Brain Stimulat. 2011;4: 169–174. doi:10.1016/j.brs.2010.11.001
- Bornochowski JP, Datta A, Huang Y, Richardson JD, Bikson M, Fridriksson J, et al.
 Targeted transcranial direct current stimulation for rehabilitation after stroke. NeuroImage.
 2013;75: 12–19. doi:10.1016/j.neuroimage.2013.02.049
- 634 20. Galletta EE, Cancelli A, Cottone C, Simonelli I, Tecchio F, Bikson M, et al. Use of
 635 Computational Modeling to Inform tDCS Electrode Montages for the Promotion of
 636 Language Recovery in Post-stroke Aphasia. Brain Stimulat. 2015;8: 1108–1115.
 637 doi:10.1016/j.brs.2015.06.018
- Fridriksson J, Rorden C, Elm J, Sen S, George MS, Bonilha L. Transcranial Direct Current
 Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical

640 Trial. JAMA Neurol. 2018;75: 1470. doi:10.1001/jamaneurol.2018.2287

- Baker JM, Rorden C, Fridriksson J. Using Transcranial Direct-Current Stimulation to Treat
 Stroke Patients With Aphasia. Stroke. 2010;41: 1229–1236.
- 643 doi:10.1161/STROKEAHA.109.576785
- Fridriksson J, Richardson JD, Baker JM, Rorden C. Transcranial Direct Current Stimulation
 Improves Naming Reaction Time in Fluent Aphasia: A Double-Blind, Sham-Controlled
 Study. Stroke. 2011;42: 819–821. doi:10.1161/STROKEAHA.110.600288
- Fridriksson J, Basilakos A, Stark BC, Rorden C, Elm J, Gottfried M, et al. Transcranial
 direct current stimulation to treat aphasia: Longitudinal analysis of a randomized controlled
 trial. Brain Stimulat. 2019;12: 190–191. doi:10.1016/j.brs.2018.09.016
- 65025.Desmond JE, Fiez JA. Neuroimaging studies of the cerebellum: language, learning and651memory. Trends Cogn Sci. 1998;2: 355–362. doi:10.1016/S1364-6613(98)01211-X
- 652 26. Murdoch BE. The cerebellum and language: Historical perspective and review. Cortex.
 653 2010;46: 858–868. doi:10.1016/j.cortex.2009.07.018
- De Smet HJ, Paquier P, Verhoeven J, Mariën P. The cerebellum: Its role in language and
 related cognitive and affective functions. Brain Lang. 2013;127: 334–342.
 doi:10.1016/j.bandl.2012.11.001
- 657 28. Sebastian R, Saxena S, Tsapkini K, Faria AV, Long C, Wright A, et al. Cerebellar tDCS: A
 658 Novel Approach to Augment Language Treatment Post-stroke. Front Hum Neurosci.
 659 2017;10. doi:10.3389/fnhum.2016.00695
- Marangolo P, Fiori V, Caltagirone C, Pisano F, Priori A. Transcranial Cerebellar Direct
 Current Stimulation Enhances Verb Generation but Not Verb Naming in Poststroke
 Aphasia. J Cogn Neurosci. 2018;30: 188–199. doi:10.1162/jocn a 01201
- 30. Sebastian R, Kim JH, Brenowitz R, Tippett DC, Desmond JE, Celnik PA, et al. Cerebellar
 neuromodulation improves naming in post-stroke aphasia. Brain Commun. 2020;2:
 fcaa179. doi:10.1093/braincomms/fcaa179
- 666 31. Pope PA, Miall RC. Task-specific facilitation of cognition by cathodal transcranial direct
 667 current stimulation of the cerebellum. Brain Stimulat. 2012;5: 84–94.
 668 doi:10.1016/j.brs.2012.03.006
- Boehringer Å, Macher K, Dukart J, Villringer A, Pleger B. Cerebellar Transcranial Direct
 Current Stimulation Modulates Verbal Working Memory. Brain Stimulat. 2013;6: 649–653.
 doi:10.1016/j.brs.2012.10.001
- 672 33. Ferrucci R, Brunoni AR, Parazzini M, Vergari M, Rossi E, Fumagalli M, et al. Modulating
 673 Human Procedural Learning by Cerebellar Transcranial Direct Current Stimulation. The
 674 Cerebellum. 2013;12: 485–492. doi:10.1007/s12311-012-0436-9
- 875 34. Roach A, Schwartz MF, Martin N, Grewal RS, Brecher A. The Philadelphia naming test:
 876 scoring and rationale. Clin Aphasiology. 1996; 121–33.
- Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L, et al. Clinical
 research with transcranial direct current stimulation (tDCS): Challenges and future
 directions. Brain Stimulat. 2012;5: 175–195. doi:10.1016/j.brs.2011.03.002
- 36. Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor
 cortex stimulation in humans. Neurology. 2001;57: 1899–1901.
 doi:10.1212/wnl.57.10.1899
- 683 37. Galea JM, Jayaram G, Ajagbe L, Celnik P. Modulation of Cerebellar Excitability by Polarity684 Specific Noninvasive Direct Current Stimulation. J Neurosci. 2009;29: 9115–9122.
 685 doi:10.1523/JNEUROSCI.2184-09.2009
- 686 38. Grimaldi G, Argyropoulos GP, Bastian A, Cortes M, Davis NJ, Edwards DJ, et al.
 687 Cerebellar Transcranial Direct Current Stimulation (ctDCS): A Novel Approach to
 688 Understanding Cerebellar Function in Health and Disease. The Neuroscientist. 2016;22:
 689 83–97. doi:10.1177/1073858414559409
- 690 39. Maddy KM, Capilouto GJ, McComas KL. The effectiveness of semantic feature analysis:

691 692		An evidence-based systematic review. Ann Phys Rehabil Med. 2014;57: 254–267.
693	40.	Oh SJ, Eom B, Park C, Sung JE. Treatment Efficacy of Semantic Feature Analyses for
694		Persons with Aphasia: Evidence from Meta-Analyses. Commun Sci Disord. 2016;21: 310-
695		323. doi:10.12963/csd.16312
696	41.	Boyle M. Semantic Feature Analysis Treatment for Aphasic Word Retrieval Impairments:
697	40	What's in a Name? Top Stroke Rehabil. 2010;17: 411–422. doi:10.1310/tsr1706-411
698	42.	Elistratiadou EA, Papathanasiou I, Holland R, Archonti A, Hilari K. A Systematic Review of
700		2018.61 $1261-1278$ doi:10.1044/2018 ISI HR-L-16-0330
700	43	Quique YM Evans WS Dickey MW Acquisition and Generalization Responses in Aphasia
702	10.	Naming Treatment: A Meta-Analysis of Semantic Feature Analysis Outcomes, Am J
703		Speech Lang Pathol, 2019:28: 230–246. doi:10.1044/2018 AJSLP-17-0155
704	44.	Boyle M, Coelho CA. Application of Semantic Feature Analysis as a Treatment for Aphasic
705		Dysnomia. Am J Speech Lang Pathol. 1995;4: 94–98. doi:10.1044/1058-0360.0404.94
706	45.	Collins AM, Loftus EF. A spreading-activation theory of semantic processing. Psychol Rev.
707		1975;82: 407–428. doi:10.1037/0033-295X.82.6.407
708	46.	Ackermann H, Wildgruber D, Daum I, Grodd W. Does the cerebellum contribute to
709		cognitive aspects of speech production? A functional magnetic resonance imaging (fMRI)
710	47	study in humans. Neurosci Lett. 1998;247: 187–190. doi:10.1016/s0304-3940(98)00328-0
711	47.	Strick PL, Dum RP, Fiez JA. Cerebellum and nonmotor function. Annu Rev Neurosci.
/ IZ 712	10	2009,32: 413–434. doi:10.1140/annurev.neuro.31.060407.125606
714	40.	of language: A critical review Brain Lang 2016:161: 4–17
715		doi:10 1016/i bandl 2015 08 003
716	49.	Goodglass H. Kaplan E. Barresi B. BDAE-3: Boston Diagnostic Aphasia Examination–
717		Third Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
718	50.	Holland AL, Fromm D, Wozniak L. CADL-3: Communication Activities of Daily Living-Third
719		Edition. Pro-ed; 2018.
720	51.	Kertesz A. WAB-R: Western Aphasia Battery-Revised. Pearson; 2007.
721	52.	Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol
722		Med. 1979;9: 139–145. doi:10.1017/S0033291700021644
723	53.	Hilari K, Byng S, Lamping DL, Smith SC. Stroke and Aphasia Quality of Life Scale-39
724		(SAQOL-39): Evaluation of Acceptability, Reliability, and Validity. Stroke. 2003;34: 1944–
725	51	1950. doi:10.1161/01.51R.0000081987.46660.ED
720	54.	factors in the controlled clinical trial. Biometrics, 1975:31: 103–115
728	55	Gravier MI Dickey MW Hula WD Evans WS Owens RI Winans-Mitrik RI et al What
729	00.	Matters in Semantic Feature Analysis: Practice-Related Predictors of Treatment Response
730		in Aphasia. Am J Speech Lang Pathol. 2018:27: 438–453. doi:10.1044/2017 AJSLP-16-
731		0196
732	56.	Evans WS, Cavanaugh R, Gravier ML, Autenreith AM, Doyle PJ, Hula WD, et al. Effects of
733		Semantic Feature Type, Diversity, and Quantity on Semantic Feature Analysis Treatment
734		Outcomes in Aphasia. Am J Speech Lang Pathol. 2021;30: 344–358.
735		doi:10.1044/2020_AJSLP-19-00112
736	57.	DeMarco AT, Dvorak E, Lacey E, Stoodley CJ, Turkeltaub PE. An Exploratory Study of
737		Cerebellar Transcranial Direct Current Stimulation in Individuals With Chronic Stroke
738	F 0	Apnasia. Cogn Benav Neurol. 2021;34: 96–106. doi:10.1097/WNN.0000000000000270
139	58.	Ganuiga PC, Hummel PC, Conen LG. Transcranial DC stimulation (IDCS): a tool for double blind sham controlled clinical studies in brain stimulation. Clin Neurophysicl Off
740 7/1		Int Fed Clin Neurophysiol. 2006:117: 845–850. doi:10.1016/j.clinph.2005.12.002
/ - 1		nt i ca oni incurophysion 2000, i i / . 040–000. uoi. i 0. i 0 10/j.chiiph.2000. i 2.000

- 59. Garra G, Singer AJ, Domingo A, Thode HC. The Wong-Baker pain FACES scale
- 743 measures pain, not fear. Pediatr Emerg Care. 2013;29: 17–20.
- 744 doi:10.1097/PEC.0b013e31827b2299
- Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, et al. Safety of
 Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimulat.
 2016;9: 641–661. doi:10.1016/j.brs.2016.06.004
- Fregni F, El-Hagrassy MM, Pacheco-Barrios K, Carvalho S, Leite J, Simis M, et al.
 Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial
 Direct Current Stimulation in Neurological and Psychiatric Disorders. Int J
 Neuropsychopharmacol. 2021;24: 256–212. doi:10.1002/jipp/pypa051
- 751 Neuropsychopharmacol. 2021;24: 256–313. doi:10.1093/ijnp/pyaa051
- 752 62. Tsapkini K, Webster KT, Ficek BN, Desmond JE, Onyike CU, Rapp B, et al. Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial. Alzheimers Dement Transl Res Clin Interv. 2018;4: 461–472.
- 755 doi:10.1016/j.trci.2018.08.002
- 756

	Study Period								
	Baseline Testing, Enrollment, & Allocation			Treatment	Post-Treatment Testing				
	Visit 1 >6 months post-stroke	Visits 2-3	Visit 4	Visits 5-19 (3-5 weeks)	Visit 20 1-week post- treatment	Visit 21 1-month post- treatment	Visit 22 3-months post- treatment	Visit 23 6-months post- treatment	
ENROLLMENT									
Informed Consent	х								
Review inclusion/exclusion criteria	x								
MRI & tDCS safety screening	х								
Medical history	x								
Current medications	х								
Neurological examination	х								
Structural medRxiv preprint doi: https://doi.org/10.1101/2024.02.05.24 (which was not certified by peer review) is the author/ It is made available	02365; this version p under, who has gran under a CC-BY 4.0	osted February 6, 20 ted medRxiv a licens nternational license .	24. The copyright ho e to display the prep	lder for this preprint int in perpetuity.					
Allocation/Randomization			х						
INTERVENTIONS									
Active tDCS or sham tDCS condition				х					
Semantic Feature Analysis (SFA) Treatment over 3-5 weeks				x					
ASSESSMENTS									
Western Aphasia Battery - Revised (WAB-R)**	х				х	х	х	х	
Computerized Philadelphia Naming Test (PNT)*		х			x	х	х	х	
Communication Activities of Daily Living (CADL)**		x			x	x	x	x	
BDAE Cookie Theft**		x			x	x	x	x	
General Health Questionnaire (GHQ)**		x			x	x	x	x	
Stroke and Aphasia Quality of Life Scale (SAQOL)**		x			x	x	x	x	
Boston Naming Test 2 nd Edition (BNT)		x							
Apraxia of Speech Rating Scale with speech sample		x							
Pyramids and Palm Trees Test Short Form (PPTT)		x							
Cognitive Linguistic Quick Test (CLQT)		x							
Record Adverse Events (AE)				x					
Record Wong-Baker FACES Pain Rating				x					

Figure 1. CeSAR schedule of enrollment, interventions, and assessments.

*primary outcome measure **secondary outcome measures

Figure1-schedule-tif